Coherus Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview

Coherus Oncology

05/08/2025 23:45

Coherus Oncology Inc CHRS.OQ CHRS.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Redwood City California-based  company is expected to report a 84.4% decrease in revenue to $10.135 million from $64.98 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Coherus Oncology Inc is for a loss of 32 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 86% above its last closing price of $0.91

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.32
-0.21
-0.35
Missed
-62.8
Dec. 31 2025
-0.18
-0.13
-0.28
Missed
-113.1
Sep. 30 2024
-0.16
-0.13
-0.01
Beat
92.5​
Jun. 30 2024
-0.29
-0.29
-0.14
Beat
51.7
​​Mar. 31 2024
-0.25
-0.24
-0.32
Missed
-32.3
Dec. 31 2023
-0.14
-0.12
-0.62
Missed
-420.3​
Sep. 30 2023
-0.29
-0.27
-0.27
Met
1.7
Jun. 30 2023
-0.48
-0.48
-0.38
Beat
21.6

This summary was machine generated August 5 at 22:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)